Cadrenal CEO Quang Pham sells 18,124 shares

Cadrenal Therapeutics director and CEO Quang X Pham reported open-market sales of company stock.

Rhea-AI Filing Summary

Cadrenal Therapeutics director and CEO Quang X Pham reported open-market sales of company stock. He sold a total of 18,124 shares of Cadrenal Therapeutics, Inc. common stock in three transactions on June 11, 12 and 15, 2026, at weighted average prices of $4.12, $3.94 and $3.58 per share.

The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham holds 132,715 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

Insider Trade Summary

Net Seller: 18,124 shares

Net Sell 4 txns

Insider Pham Quang X

Role Chairman, CEO and Interim CFO

Sold 18,124 shs ($70K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,666	$3.58	$13K
Sale	Common Stock	12,996	$3.94	$51K
Sale	Common Stock	1,462	$4.12	$6K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 132,715 shares (Direct); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)

Footnotes (5)

1. F1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.09 through $4.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.22 through $3.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

Key Figures

Total shares sold: 18,124 shares June 11, 2026 sale: 1,462 shares at $4.12/share June 12, 2026 sale: 12,996 shares at $3.94/share +4 more

7 metrics

Total shares sold 18,124 shares Net open-market sales disclosed in this Form 4

June 11, 2026 sale 1,462 shares at $4.12/share Open-market sale of common stock

June 12, 2026 sale 12,996 shares at $3.94/share Open-market sale of common stock

June 15, 2026 sale 3,666 shares at $3.58/share Open-market sale of common stock

Direct holdings after trades 132,715 shares Common stock directly owned by Quang X Pham

Indirect trust holdings 200,000 shares Common stock held by The PVBQ Living Trust

Trading plan adoption date September 25, 2025 Rule 10b5-1 trading arrangement for reported sales

Key Terms

Rule 10b5-1 trading arrangement, weighted average price, open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 trading arrangement regulatory

"Shares were sold in accordance with a Rule 10b5-1 trading arrangement adopted on September 25, 2025."

weighted average price financial

"The price reported is a weighted average price for multiple sale transactions within a price range."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"Transactions are coded as open-market sale or private transaction of common stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"Common stock is held as indirect ownership through The PVBQ Living Trust."

sole voting and dispositive power regulatory

"Quang Pham, as trustee, has sole voting and dispositive power over shares owned by The PVBQ Living Trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did Cadrenal Therapeutics (CVKD) disclose?

Cadrenal Therapeutics reported that Chairman and CEO Quang X Pham sold 18,124 shares of common stock in three open-market transactions. The sales occurred on June 11, 12 and 15, 2026, at weighted average prices between $3.58 and $4.12 per share.

At what prices did Quang X Pham sell Cadrenal Therapeutics (CVKD) shares?

Quang X Pham sold Cadrenal Therapeutics common stock at weighted average prices of $4.12, $3.94 and $3.58 per share. Footnotes explain each reported price reflects multiple trades within ranges from $3.22 to $4.23 per share across the three transaction dates.

How many Cadrenal Therapeutics (CVKD) shares does Quang X Pham hold after the sales?

After the reported sales, Quang X Pham holds 132,715 Cadrenal Therapeutics common shares directly. He also has indirect ownership of 200,000 additional shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.

Were the Cadrenal Therapeutics (CVKD) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the shares sold by Quang X Pham were transacted under a Rule 10b5-1 trading arrangement. This pre-arranged plan was adopted on September 25, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.

What role does The PVBQ Living Trust play in Cadrenal Therapeutics (CVKD) ownership?

The PVBQ Living Trust holds 200,000 shares of Cadrenal Therapeutics common stock attributed as indirect ownership to Quang X Pham. He is trustee of the trust and has sole voting and dispositive power over these shares, while his child is the trust’s sole beneficiary.

How many Cadrenal Therapeutics (CVKD) insider sale transactions were reported?

The Form 4 shows three non-derivative open-market sale transactions of Cadrenal Therapeutics common stock. Together, they total 18,124 shares sold, and all are coded as sales, with no option exercises, gifts, or tax-withholding dispositions reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 08:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FLORIDA 32082

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, CEO and Interim CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		S		1,462(1)	D	$4.12(2)	149,377	D
Common Stock	06/12/2026		S		12,996(1)	D	$3.94(3)	136,381	D
Common Stock	06/15/2026		S		3,666(1)	D	$3.58(4)	132,715	D
Common Stock								200,000	I	The PVBQ Living Trust(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.09 through $4.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.22 through $3.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Quang X. Pham	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)